Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 2
1998 3
1999 2
2000 4
2001 13
2002 11
2003 18
2004 17
2005 19
2006 37
2007 46
2008 40
2009 52
2010 35
2011 28
2012 47
2013 89
2014 102
2015 129
2016 130
2017 65
2018 72
2019 75
2020 114
2021 102
2022 140
2023 131
2024 127
2025 151
2026 198
2027 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,735 results

Results by year

Filters applied: . Clear all
Page 1
Amendment „Neue Nomenklatur zur MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease; metabolische Dysfunktion assoziierte steatotische Lebererkrankung)“ zur S2k-Leitlinie „Nicht-alkoholische Fettlebererkrankung“ (v.2.0/April 2022) der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS).
Roeb E, Canbay A, Bantel H, Bojunga J, de Laffolie J, Demir M, Denzer UW, Geier A, Hofmann WP, Hudert C, Karlas T, Krawczyk M, Longerich T, Lüdde T, Roden M, Schattenberg JM, Sterneck M, Tannapfel A, Lorenz P, Tacke F; Collaborators. Roeb E, et al. Among authors: demir m. Z Gastroenterol. 2024 Jul;62(7):1077-1087. doi: 10.1055/a-2309-6052. Epub 2024 Jul 8. Z Gastroenterol. 2024. PMID: 38976985 German. No abstract available.
Update der S3-Leitlinie „Seltene Lebererkrankungen (LeiSe LebEr) – Autoimmune Lebererkrankungen von der Pädiatrie bis zum Erwachsenenalter“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – Living guideline.
Sebode M, Bantel H, Baumann U, Bufler P, Demir M, Dold L, Keitel-Anselmino V, Klein R, Kremer AE, Jansen PL, Melter M, Schirmacher P, Schramm C, Sterneck M, Strassburg CP, Weiler-Normann C, Lohse AW; für die Autoren des DGVS Leitlinienkomitees/for the authors of the DGVS guideline committee; Collaborators. Sebode M, et al. Among authors: demir m. Z Gastroenterol. 2026 May;64(5):528-617. doi: 10.1055/a-2769-2475. Epub 2026 May 20. Z Gastroenterol. 2026. PMID: 42161255 Free article. German. No abstract available.
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial.
Levy C, Abouda GF, Bilir BM, Bonder A, Bowlus CL, Campos-Varela I, Cazzagon N, Chandok N, Cheent K, Cortez-Pinto H, Demir M, Dill MT, Eksteen B, Fenkel JM, Gilroy R, Ko HH, Jacobson IM, Kallis Y, Kugelmas M, Luketic V, Mangia A, Montano-Loza AJ, Mukhopadhya A, Olveira A, Patel BC, Pietrangelo A, Pradhan F, Salcedo M, Shiffman ML, Sprinzl K, Swann R, Thorburn D, Thuluvath PJ, Trivedi PJ, Turnes J, Zein CO, Gomes da Silva H, Jaitly S, Miller B, Milligan C, Tavenard A, Kowdley KV. Levy C, et al. Among authors: demir m. J Hepatol. 2026 Jan;84(1):74-85. doi: 10.1016/j.jhep.2025.04.025. Epub 2025 May 10. J Hepatol. 2026. PMID: 40350321 Free article. Clinical Trial.
Hyperkalemia risk with finerenone in diabetic kidney disease: a real-world analysis from the FINE-TURK cohort.
Özdede M, Yadigar S, Güven AT, Akgür S, Arslan F, Sezen M, Özcan B, Ayaz EY, Doğantekin B, Atay İ, Değer SM, Demir M, Koyuncu S, Yılmaz Ü, İnci A, Çolak H, Demirelli B, Tuğlular S, Oguz EG, Ayli MD, Avanaz E, Yılmaz F, Doğan B, Karaköse S, Karakan MŞ, Demirci BG, Türkmen K, Baloğlu İ, Batmazoğlu M, Mert M, Aydın E, Aydın FY, Parmaksız E, Özdemir P, Ediz B, Aydın Z, Demir ME, Sezer S, Ünver S, Baykal Ö, Akman B, Altuntaş A, İslam M, Koçak SY, Mert M, Dursun B, Eren N, Demir SB, Bilgiç MA, Erdut A, Keskin G, Horoz M, Şahin AZ, Tekinyıldız M, Duranay M, Yalın SF, Umut HMY, Altunok M, Sarı R, Sarı F, Torun D, Kahvecioğlu S, Karatutlu AS, Akagün T, Çelik H, Kazan S, Öztürk İ, Polat M, Aydın MF, Meşe M, Demirezen A, Derici Ü, Altun E, Bakırdöğen S, Kara E, Akgöl C, Aykent MB, İlter A, Ekmekci A, Ulu S, Arıcı M, Şengül E, Bakır EA. Özdede M, et al. Among authors: demir me, demir m. Clin Kidney J. 2026 Jul 6;19(8):sfag227. doi: 10.1093/ckj/sfag227. eCollection 2026 Aug. Clin Kidney J. 2026. PMID: 42592375 Free PMC article.
Bile salt hydrolase activity as a rational target for MASLD therapy.
Jones EV, Wang Y, Wei W, Reed JC, Chaudhari SN, Li DK, Boursier J, Lang S, Demir M, Diehl AM, Allegretti AS, Schnabl B, Chung RT, Devlin AS. Jones EV, et al. Among authors: demir m. Gut Microbes. 2026 Dec 31;18(1):2608437. doi: 10.1080/19490976.2025.2608437. Epub 2026 Jan 2. Gut Microbes. 2026. PMID: 41481156 Free PMC article.
Gut microbial ethanol metabolism contributes to auto-brewery syndrome in an observational cohort.
Hsu CL, Shukla S, Freund L, Chou AC, Yang Y, Bruellman R, Raya Tonetti F, Cabré N, Mayo S, Lim HG, Magallan V, Cordell BJ, Lang S, Demir M, Stärkel P, Llorente C, Palsson BO, Mandyam C, Boland BS, Hohmann E, Schnabl B. Hsu CL, et al. Among authors: demir m. Nat Microbiol. 2026 Feb;11(2):415-428. doi: 10.1038/s41564-025-02225-y. Epub 2026 Jan 8. Nat Microbiol. 2026. PMID: 41507585 Free PMC article.
Therapeutic plasma exchange in amatoxin associated acute liver failure-results from the multi-center Amanita-PEX study.
Stahl K, Nalbant B, Pape T, Breteau I, Coirier V, Cardoso FS, de Haan J, Janik MK, Wasmuth JC, Madaleno J, Merle U, Frohme J, Tepasse PR, Müller M, Große K, Linke A, Mareljic N, Larsen FS, Dahlqvist G, Kolev M, Schulze M, Willuweit K, Janke-Maier P, Dondorf F, Fierro-Angulo ÓM, Geerts A, Toapanta D, Dejean C, Alharthi M, Reverter E, Schenk H, Raevens S, Macías-Rodríguez RU, Rauchfuß F, Berg CP, Schmidt H, Geier A, Semmo N, Lanthier N, Bjerring PN, Lange CM, Sterneck M, Bruns T, Schmid S, van de Loo D, Demir M, Boettler T, Borges C, Nattermann J, Wronka K, den Hoed CM, Marques HP, Artru F, Levesque E, Wedemeyer H, Campos-Murguia A, Taubert R; Amanita-PEX-study group. Stahl K, et al. Among authors: demir m. Crit Care. 2025 Oct 30;29(1):458. doi: 10.1186/s13054-025-05560-y. Crit Care. 2025. PMID: 41163058 Free PMC article.
Docetaxel associated myositis.
Demırel N, Demır M. Demırel N, et al. Among authors: demir m. J Chemother. 2026 Jul;38(4):404-409. doi: 10.1080/1120009X.2025.2505806. Epub 2025 May 20. J Chemother. 2026. PMID: 40395000
Malignancy in Adults with Inborn Errors of Immunity: A Retrospective Single-Center Study.
Gumusburun R, Yıldırım O, Karakoc M, Okan K, Inan S, Dalgıc CT, Akten HS, Bogatekin G, Bulut G, Demir M, Aytac H, Camyar A, Ozısık M, Demir D, Soyer N, Soylu M, Uysal FE, Aykut A, Durmaz A, Ozgul S, Sin AZ, Ardeniz O. Gumusburun R, et al. Among authors: demir m. J Clin Immunol. 2025 Sep 25;45(1):128. doi: 10.1007/s10875-025-01910-1. J Clin Immunol. 2025. PMID: 40993321 Free PMC article.
1,735 results